insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

QNCX Quince Therapeutics, Inc. - 8-K

Filed Apr 22, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001193125-26-170572
5.02

Item 5.02 - Departure/Election of Directors or Certain Officers

327 words

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Director

On April 22, 2026, the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”) increased the number of directors on the Board to four and appointed June Bray as a Class I director of the Company to fill the resulting vacancy, effective immediately, to serve until the 2026 Annual Meeting of Stockholders, or until her earlier death, disqualification, resignation or removal. The Board has determined that Ms. Bray is an independent director under the listing standards of the Nasdaq Stock Market. Ms. Bray was also appointed to serve on the Nominating & Governance Committee, Audit Committee, and Compensation Committee of the Board.

There are no family relationships between Ms. Bray and any director or executive officer of the Company and Ms. Bray does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with Ms. Bray’s appointment to the Board, Ms. Bray will receive the standard compensation received by non-employee directors in accordance with the Company’s Outside Director Compensation Policy (“Policy”), which was last previously filed by the Company as Exhibit 10.14 to the Annual Report on Form 10-K filed with the SEC on April 10, 2026, expect that she will not receive a grant of options in connection with her appointment as a director. In accordance with the Policy, Ms. Bray is entitled to receive a $38,000 annual retainer for service as a Board member, plus $7,500, $5,500, and $4,000 annual retainers for her service on the Nominating & Governance Committee, Audit Committee, and Compensation Committee of the Board.

Ms. Bray will also enter the Company’s standard form of indemnification agreement, which was previously filed by the Company as Exhibit 10.4 to the Annual Report on Form 10-K filed with the SEC on April 10, 2026.